Intestinal uptake of insulin nanoparticles: Facts or myths?

Current Pharmaceutical Biotechnology

Volumn 15, Issue 7, 2014, Pages 629-638

  Lopes, Marlene A ^a   Abrahim, Bárbara A ^a,b   Seiça, Raquel ^c   Veiga, Francisco ^a   Rodrigues, Carlos R ^b   Ribeiro, António J ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Absorption mechanisms; Bioavailability; Insulin; Nanoparticle; Oral administration

Indexed keywords

INSULIN; NANOPARTICLE; ANTIDIABETIC AGENT;

ABSORPTION; ARTICLE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG UPTAKE; GASTROINTESTINAL TRACT FUNCTION; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN METABOLISM; INSULIN TREATMENT; NANOENCAPSULATION; TREATMENT OUTCOME; ANIMAL; BIOAVAILABILITY; DRUG DELIVERY SYSTEM; INTESTINE ABSORPTION; INTESTINE MUCOSA; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; NANOPARTICLES;

EID: 84925850213     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140915151319     Document Type: Article

References (114)

1. Hirai, S.; Ikenaga, T.; Matsuzawa, T. Nasal absorption of insulin in dogs. Diabetes, 1978, 27, 296-299.
2. Zhang, L.; Song, L.; Zhang, C.; Ren, Y. Improving intestinal insulin absorption efficiency through coadministration of cellpenetrating peptide and hydroxypropyl-beta-cyclodextrin. Carbohydr. Polym., 2012, 87 (2), 1822-1827
3. Plapied, L.; Duhem, N.; des Rieux, A.; Préat, V. Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid Interface Sci., 2011, 16 (3), 228-237.
4. Gerich, J. E. Novel insulins: Expanding options in diabetes management. Am. J. Med., 2002, 113 (4), 308-316.
5. Brange, J.; Langkjaer, L. Insulin formulation and delivery. Pharm. Biotechnol., 1997, 10, 343-409.
6. Adams, G. G.; Harding, S. E. Drug delivery systems for the treatment of diabetes mellitus: State of the art. Curr. Pharm. Des., 2013, 19 (41), 7244-7263.
7. Owens, D.; Zinman, B.; Bolli, G. Alternative routes of insulin delivery. Diabet. Med., 2003, 20 (11), 886-898.
8. Roger, E.; Lagarce, F.; Garcion, E.; Benoit, J. P. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J. Control. Release, 2009, 140 (2), 174-181.
9. Antosova, Z.; Mackova, M.; Kral, V.; Macek, T. Therapeutic application of peptides and proteins: Parenteral forever? Trends Biotechnol., 2009, 27 (11), 628-635.
10. Makhlof, A.; Werle, M.; Tozuka, Y.; Takeuchi, H. A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J. Control. Release, 2011, 149 (1), 81-88.
11. Reis, C. P.; Veiga, F. J.; Ribeiro, A. J.; Neufeld, R. J.; Damgé, C. Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J. Pharm. Sci., 2008, 97 (12), 5290-5305.
12. Hussain, N.; Florence, A. T. Utilizing bacterial mechanisms of epithelial cell entry: Invasin-induced oral uptake of latex nanoparticles. Pharm. Res., 1998, 15 (1), 153-156.
13. Jani, P.; Halbert, G. W.; Langridge, J.; Florence, A. T. Nanoparticle uptake by the rat gastrointestinal mucosa-quantitation and particlesize dependency. J. Pharm. Pharmacol., 1990, 42 (12), 821-826.
14. Cheng, H.; Leblond, C. P. Origin, differentiation and renewal of 4 main epithelial-cell types in mouse small intestine 1. Columnar cell. Am. J. Anat., 1974, 141 (4), 531-561.
15. Hilgendorf, C.; Spahn-Langguth, H.; Regardh, C. G.; Lipka, E.; Amidon, G. L.; Langguth, P. Caco-2 versus Caco-2/HT29 cocultured cell lines: Permeabilities via diffusion, inside-and outsidedirected carrier-mediated transport. J. Pharm. Sci., 2000, 89 (1), 63-75.
16. Laukoetter, M. G.; Bruewer, M.; Nusrat, A. Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr. Opin. Gastroen., 2006, 22 (2), 85-89.
17. Yang, Q.; Bermingham, N. A.; Finegold, M. J.; Zoghbi, H. Y. Requirement of secretory cell lineage commitment in the mouse intestine. Science, 2001, 294 (5549), 2155-2158.
18. Sjoblom, M.; Safsten, B.; Flemstrom, G. Melatonin-induced calcium signaling in clusters of human and rat duodenal enterocytes. Am. J. Pshysiol.-Gastr. L, 2003, 284 (6), G1034-G1044.
19. Specian, R. D.; Oliver, M. G. Functional biology of intestinal goblet cells. Am. J. Physiol., 1991, 260, C183-C193.
20. Jin, Y.; Song, Y.; Zhu, X.; Zhou, D.; Chen, C.; Zhang, Z.; Huang, Y. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials., 2012, 33 (5), 1573-1582.
21. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y.-J.; Préat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control. Release, 2006, 116 (1), 1-27.
22. Behrens, I.; Pena, A. I. V.; Alonso, M. J.; Kissel, T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: The effect of mucus on particle adsorption and transport. Pharm. Res., 2002, 19 (8), 1185-1193.
23. Wang, Y.-Y.; Lai, S. K.; Suk, J. S.; Pace, A.; Cone, R.; Hanes, J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew. Chem. Int. Ed., 2008, 47 (50), 9726-9729.
24. Zhao, B.; Sun, L.; Zhang, W.; Wang, Y.; Zhu, J.; Zhu, X.; Yang, L.; Li, C.; Zhang, Z.; Zhang, Y. Secretion of intestinal goblet cells: A novel excretion pathway of nanoparticles. Nanomedicine, 2014, 10 (4), 839-849.
25. Corr, S.C.; Gahan, C.C.G.M.; Hill, C. M-cells: Origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol. Med. Microbiol., 2008, 52 (1), 2-12.
26. Gebert, A.; Rothkotter, H. J.; Pabst, R. M cells in Peyer's patches of the intestine. Int. Rev. Cytol., 1996, 167, 91-159.
27. Neutra, M. R.; Mantis, N. J.; Kraehenbuhl, J. P. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nature Immunol., 2001, 2 (11), 1004-1009.
28. Giannasca, P. J.; Giannasca, K. T.; Leichtner, A. M.; Neutra, M. R. Human intestinal M cells display the sialyl lewis a antigen. Infect. Immun., 1999, 67 (2), 946-953.
29. Brayden, D. J.; Jepson, M. A.; Baird, A. W. Intestinal Peyer's patch M cells and oral vaccine targeting. Drug. Discov. Today Technol., 2005, 10 (17), 1145-1157.
30. Roger, E.; Lagarce, F.; Garcion, E.; Benoit, J. P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine, 2010, 5 (2), 287-306.
31. Mach, J.; Hshieh, T.; Hsieh, D.; Grubbs, N.; Chervonsky, A. Development of intestinal M cells. Immunol. Rev., 2005, 206, 177-189.
32. Alexander T. F. Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Discov. Today Technol., 2005, 2 (1), 75-81.
33. Chen, M.-C.; Sonaje, K.; Chen, K.-J.; Sung, H.-W. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials, 2011, 32 (36), 9826-9838.
34. Kerneis, S.; Bogdanova, A.; Colucci Guyon, E.; Kraehenbuhl, J. P.; Pringault, E. Cytosolic distribution of villin in M cells from mouse Peyer's patches correlates with the absence of a brush border. Gastroenterol., 1996, 110 (2), 515-521.
35. Clark, M. A.; Hirst, B. H.; Jepson, M. A. M-cell surface beta-1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells. Infect. Immun., 1998, 66 (3), 1237-1243.
36. Garinot, M.; Fiévez, V.; Pourcelle, V.; Stoffelbach, F.; des Rieux, A.; Plapied, L.; Theate, I.; Freichels, H.; Jérôme, C.; Marchand-Brynaert, J.; Schneider, Y.-J.; Préat, V. Pegylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release, 2007, 120 (3), 195-204.
37. Neutra, M. R. Current concepts in mucosal immunity. Role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system. Am. J. Pshysiol.-Gastr. L, 1998, 274 (5), G785-G791.
38. Neutra, M. R.; Frey, A.; Kraehenbuhl, J. P. Epithelial M cells: Gateways for mucosal infection and immunization. Cell, 1996, 86 (3), 345-348.
39. Frey, A.; Neutra, M. R. Targeting of mucosal vaccines to Peyer's patch M cells. Behring Institute Mitteilungen, 1997, (98), 376-89.
40. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y. J.; Preat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control. Release, 2006, 116 (1), 1-27.
41. Peppas, N. A.; Carr, D. A. Impact of absorption and transport on intelligent therapeutics and nanoscale delivery of protein therapeutic agents. Chem. Eng. Sci., 2009, 64 (22), 4553-4565.
42. Binder, C. L., Torsten; Ole Faber, M. D.; Stig Pramming, M. D. Insulin pharmacokinetics. Diabetes Care, 1984, 7, 188-199.
43. Evans, D. F.; Pye, G.; Bramley, R.; Clark, A. G.; Dyson, T. J.; Hardcastle, J. D. Measurement of gastrointestinal pH profiles in normal ambulant human-subjects. Gut, 1988, 29 (8), 1035-1041.
44. Sood, A.; Panchagnula, R. Peroral route: An opportunity for protein and peptide drug delivery. Chem. Rev., 2001, 101 (11), 3275-3303.
45. Pappenheimer, J. R.; Reiss, K. Z. Contribution of solvent drag through intercellular-junctions to absorption of nutrients by the small-intestine of the rat. J. Membr. Biol., 1987, 100 (2), 123-136.
46. Korjamo, T.; Heikkinen, A.; Waltari, P.; Mönkkönen, J. The asymmetry of the unstirred water layer in permeability experiments. Pharm. Res., 2008, 25 (7), 1714-1722.
47. Fagerholm, U.; Lennernäs, H. Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. Eur. J. Pharm. Sci., 1995, 3 (5), 247-253.
48. Atuma, C.; Strugala, V.; Allen, A.; Holm, L. The adherent gastrointestinal mucus gel layer: Thickness and physical state in vivo. Am. J. Pshysiol.-Gastr. L, 2001, 280 (5), G922-G929.
49. Strous, G. J.; Dekker, J. Mucin-type glycoproteins. Crit. Rev. Biochem. Mol., 1992, 27 (1-2), 57-92.
50. Norris, D. A.; Puri, N.; Sinko, P. J. The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug. Deliv. Rev., 1998, 34 (2-3), 135-154.
51. Salamat-Miller, N.; Chittchang, M.; Johnston, T. P. The use of mucoadhesive polymers in buccal drug delivery. Adv. Drug Deliv. Rev, 2005, 57 (11), 1666-1691.
52. Bernkop-Schnurch, A.; Schwarz, V.; Steininger, S. Polymers with thiol groups: A new generation of mucoadhesive polymers? Pharmaceut. Res., 1999, 16 (6), 876-881.
53. Andrews, C. W.; Bennett, L.; Yu, L. X. Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship. Pharmaceut. Res., 2000, 17 (6), 639-644.
54. Hamman, J. H.; Enslin, G. M.; Kotze, A. F. Oral delivery of peptide drugs-barriers and developments. BioDrugs, 2005, 19 (3), 165-177.
55. Nellans, H. N. Mechanisms of peptide and protein-absorption. Paracellular intestinal transport-modulation of absorption. Adv. Drug Deliv. Rev., 1991, 7 (3), 339-364.
56. Sonaje, K.; Chuang, E. Y.; Lin, K. J.; Yen, T. C.; Su, F. Y.; Tseng, M. T.; Sung, H. W. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: Microscopic, ultrastructural, and computed-tomographic observations. Mol. Pharm., 2012, 9 (5), 1271-1279.
57. Bernkop-Schnurch, A.; Krauland, A.H.; Leitner, V.M.; Palmberger, T. Thiomers: Potential excipients for non-invasive peptide delivery systems. Eur. J. Pharm. Biopharm., 2004, 58 (2), 253-263.
58. Dave, N.; Hazra, P.; Khedkar, A.; Manjunath, H. S.; Iyer, H.; Suryanarayanan, S. Process and purification for manufacture of a modified insulin intended for oral delivery. J. Chromatogr. A, 2008, 1177 (2), 282-286.
59. Su, F.-Y.; Lin, K.-J.; Sonaje, K.; Wey, S.-P.; Yen, T.-C.; Ho, Y.-C.; Panda, N.; Chuang, E.-Y.; Maiti, B.; Sung, H.-W. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials, 2012, 33 (9), 2801-11.
60. Bernkop-Schnurch, A.; Schmitz, T. Presystemic metabolism of orally administered peptide drugs and strategies to overcome it. Curr. Drug. Metab., 2007, 8 (5), 509-517.
61. Asada, H.; Douen, T.; Waki, M.; Adachi, S.; Fujita, T.; Yamamato, A.; Muranishi, S. Absorption characteristics of chemically modified-insulin derivatives with various fatty-acids in the small and large-intestine. J. Pharm. Sci., 1995, 84 (6), 682-687.
62. Morishita, M.; Kamei, N.; Ehara, J.; Isowa, K.; Takayama, K. A novel approach using functional peptides for efficient intestinal absorption of insulin. J. Control. Release, 2007, 118 (2), 177-184.
63. Chalasani, K. B.; Russell-Jones, G. J.; Yandrapu, S. K.; Diwan, P. V.; Jain, S. K. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J. Control. Release, 2007, 117 (3), 421-429.
64. Petrus, A. K.; Vortherms, A. R.; Fairchild, T. J.; Doyle, R. P. Vitamin B12 as a carrier for the oral delivery of insulin. Chem. Med. Chem., 2007, 2 (12), 1717-1721.
65. Sajeesh, S.; Sharma, C. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int. J. Pharm., 2006, 325 (1-2), 147-54.
66. Morishita, M.; Goto, T.; Nakamura, K.; Lowman, A.M.; Takayama, K.; Peppas, N. A. Novel oral insulin delivery systems based on complexation polymer hydrogels: Single and multiple administration studies in type 1 and 2 diabetic rats. J. Control. Release, 2006, 110 (3), 587-594.
67. Gong, R. M.; Li, C. C.; Zhu, S. X.; Zhang, Y. Y.; Du, Y.; Jiang, J. H. A novel pH-sensitive hydrogel based on dual crosslinked alginate/-alpha-glutaric acid chitosan for oral delivery of protein. Carbohydr. Polym., 2011, 85 (4), 869-874.
68. Zhang, N.; Ping, Q. N.; Huang, G. H.; Xu, W. F. Investigation of lectin-modified insulin liposomes as carriers for oral administration. Int. J. Pharm., 2005, 294 (1-2), 247-259.
69. Lin, Y.-H.; Chen, C.-T.; Liang, H.-F.; Kulkarni, A. R.; Lee, P.-W.; Chen, C.-H.; Sung, H.-W. Novel nanoparticles for oral insulin delivery via the paracellular pathway. Nanotechnology, 2007, 18 (10).
70. Katsuma, M.; Watanabe, S.; Kawai, H.; Takemura, S.; Sako, K. Effects of absorption promoters on insulin absorption through colon-targeted delivery. Int. J. Pharm., 2006, 307 (2), 156-162.
71. Maroni, A.; Zema, L.; Del Curto, M. D.; Foppoli, A.; Gazzaniga, A. Oral colon delivery of insulin with the aid of functional adjuvants. Adv. Drug Deliv. Rev., 2012, 64 (6), 540-556.
72. Paul McGee, J.; Davis, S. S.; O'Hagan, D. T. Zero order release of protein from poly(D,L-lactide-co-glycolide) microparticles prepared using a modified phase separation technique. J. Control. Release, 1995, 34 (2), 77-86.
73. Orci, L.; Malaisselagae, F.; Ravazzola, M.; Rouiller, D.; Renold, A. E.; Perrelet, A.; Unger, R. Morphological basis for intercellular communication between alpha-cells and beta-cells in endocrine pancreas. J. Clin. Invest., 1975, 56 (4), 1066-1070.
74. Sonaje, K.; Lin, K. J.; Wang, J. J.; Mi, F. L.; Chen, C. T.; Juang, J. H.; Sung, H. W. Self-assembled pH-sensitive nanoparticles: A platform for oral delivery of protein drugs. Adv. Funct. Mater., 2010, 20 (21), 3695-3700.
75. Lin, Y. H.; Mi, F. L.; Chen, C. T.; Chang, W. C.; Peng, S. F.; Liang, H. F.; Sung, H. W. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules, 2007, 8 (1), 146-152.
76. Daugherty, A. L.; Mrsny, R. J. Transcellular uptake mechanisms of the intestinal epithelial barrier-part one. Pharm. Sci. Technol. To., 1999, 2 (4), 144-151.
77. Fasano, A. Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol., 1998, 16 (4), 152-157.
78. Francis, M. F.; Cristea, M.; Winnik, F. M. Polymeric micelles for oral drug delivery: Why and how. Pure. Appl. Chem., 2004, 76(7-8), 1321-1335.
79. Mathot, F.; Schanck, A.; Van Bambeke, F.; Arien, A.; Noppe, M.; Brewster, M.; Preat, V. Passive diffusion of polymeric surfactants across lipid bilayers. J. Control. Release, 2007, 120 (1-2), 79-87.
80. Mathot, F.; Rieux, A. D.; Arien, A.; Schneider, Y. J.; Brewster, M.; Preat, V. Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier. J. Control. Release, 2007, 124 (3), 134-143.
81. Zha, L.Y.; Xu, Z.R.; Wang, M.Q.; Gu, L.Y. Chromium nanoparticle exhibits higher absorption efficiency than chromium picolinate and chromium chloride in Caco-2 cell monolayers. J. Anim. Physiol. Anim. Nutr., 2008, 92 (2), 131-140.
82. Blanchette, J.; Kavimandan, N.; Peppas, N. A. Principles of transmucosal delivery of therapeutic agents. Biomed. Pharmacother., 2004, 58 (3), 142-151.
83. Iversen, T. G.; Skotland, T.; Sandvig, K. Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. Nano Today, 2011, 6 (2), 176-185.
84. Plapied, L.; Duhem, N.; des Rieux, A.; Preat, V. Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid. In., 2011, 16 (3), 228-237.
85. des Rieux, A.; Fievez, V.; Theate, I.; Mast, J.; Preat, V.; Schneider, Y.-J. An improved in vitro model of human intestinal follicleassociated epithelium to study nanoparticle transport by M cells. European J. Pharm. Sci., 2007, 30 (5), 380-391.
86. des Rieux, A.; Fievez, V.; Momtaz, M.; Detrembleur, C.; Alonso-Sande, M.; Van Gelder, J.; Cauvin, A.; Schneider, Y. J.; Preat, V. Helodermin-loaded nanoparticles: Characterization and transport across an in vitro model of the follicle-associated epithelium. J. Control. Release, 2007, 118 (3), 294-302.
87. Yoncheva, K.; Guembe, L.; Campanero, M. A.; Irache, J. M. Evaluation of bioadhesive potential and intestinal transport of pegylated poly(anhydride) nanoparticles. Int. J. Pharm., 2007, 334 (1-2), 156-165.
88. Florence, A.T. The oral absorption of micro-and nanoparticulates: Neither exceptional nor unusual. Pharmaceut. Res., 1997, 14 (3), 259-266.
89. Hillaireau, H.; Couvreur, P. Nanocarriers' entry into the cell: Relevance to drug delivery. Cell. Mol. Life Sci., 2009, 66 (17), 2873-2896.
90. Conner, S. D.; Schmid, S. L. Regulated portals of entry into the cell. Nature, 2003, 422 (6927), 37-44.
91. Kiyono, H.; Fukuyama, S. Nalt-versus Peyer's-patch-mediated mucosal immunity. Nature Rev. Immunol., 2004, 4 (9), 699-710.
92. Tyrer, P.; Foxwell, A.R.; Cripps, A.W.; Apicella, M.A.; Kyd, J.M. Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium. Infect. Immun., 2006, 74 (1), 625-631.
93. Pabst, O.M., A.M. Oral tolerance to food protein. Mucosal. Immunol., 2012, 5 (3), 232-239.
94. Shantha, T. R. S., J. G. Inhalation insulin and oral and nasal insulin sprays for diabetics: Panacea or evolving future health disaster part ii. Townsend Letter, 2009, 106-110.
95. Sarmento, B.; Ferreira, D. C.; Jorgensen, L.; van de Weert, M. Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles. Eur. J. Pharm. Biopharm., 2007, 65 (1), 10-17.
96. Carino, G. P.; Jacob, J. S.; Mathiowitz, E. Nanosphere based oral insulin delivery. J. Control. Release, 2000, 65 (1-2), 261-269.
97. Jia, X. Y.; Chen, X.; Xu, Y. L.; Han, X. Y.; Xu, Z. R. Tracing transport of chitosan nanoparticles and molecules in Caco-2 cells by fluorescent labeling. Carbohyd. Polym., 2009, 78 (2), 323-329.
98. Gullberg, E.; Leonard, M.; Karlsson, J.; Hopkins, A. M.; Brayden, D.; Baird, A. W.; Artursson, P. Expression of specific markers and particle transport in a new human intestinal M-cell model. Biochem. Bioph. Res. Co., 2000, 279 (3), 808-813.
99. Takeuchi, H.; Yamamoto, H.; Kawashima, Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev., 2001, 47 (1), 39-54.
100. Sarmento, B.; Ribeiro, A.; Veiga, F.; Ferreira, D.; Neufeld, R. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromol., 2007, 8 (10), 3054-3060.
101. Xiaoyang, L.; Jianping, Q.; Yunchang, X.; Xi, Z.; Shunwen, H.; Ying, X.; Yi, L.; Wei, W. Nanoemulsions coated with alginate/chitosan as oral insulin delivery systems: Preparation, characterization, and hypoglycemic effect in rats. Int. J. Nanomedicine, 2012, 8.
102. Elsayed, A.; Remawi, M. A.; Qinna, N.; Farouk, A.; Badwan, A. Formulation and characterization of an oily-based system for oral delivery of insulin. Eur. J. Pharm. Biopharm., 2009, 73 (2), 269-279.
103. Quellhorst, E. Insulin therapy during peritoneal dialysis: Pros and cons of various forms of administration. J. Am. Soc. Nephrol., 2002, 13 (suppl 1), S92-S96.
104. Heinemann, L.; Jacques, Y. Oral insulin and buccal insulin: A critical reappraisal. J. Diabetes. Sci. Technol., 2009, 3 (3), 568-84.
105. Zhang, X.; Sun, M.; Zheng, A.; Cao, D.; Bi, Y.; Sun, J. Preparation and characterization of insulin-loaded bioadhesive plga nanoparticles for oral administration. Eur. J. Pharm. Sci., 2012, 45 (5), 632-638.
106. Wu, Z.M.; Zhou, L.; Guo, X.D.; Jiang, W.; Ling, L.; Qian, Y.; Luo, K.Q.; Zhang, L.J. HP55-coated capsule containing PLGA/ RS nanoparticles for oral delivery of insulin. Int. J. Pharm., 2012, 425 (1-2), 1-8.
107. Damge, C.; Maincent, P.; Ubrich, N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release, 2007, 117 (2), 163-170.
108. Sonaje, K.; Chen, Y. J.; Chen, H. L.; Wey, S. P.; Juang, J. H.; Nguyen, H. N.; Hsu, C. W.; Lin, K. J.; Sung, H. W. Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials., 2010, 31 (12), 3384-3394.
109. Fonte, P.; Nogueira, T.; Gehm, C.; Ferreira, D.; Sarmento, B. Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv. and Transl. Res., 2011, 1 (4), 299-308.
110. Woitiski, C.; Neufeld, R.; Veiga, F.; Carvalho, R.; Figueiredo, I. Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur J. Pharm. Sci., 2010, 41 (3), 556-563.
111. Prusty, A. K.; Sahu, S. K. Development and evaluation of insulin incorporated nanoparticles for oral administration. ISRN Nanotechnol., 2013, 2013, 6.
112. Han, L.; Zhao, Y.; Yin, L.; Li, R.; Liang, Y.; Huang, H.; Pan, S.; Wu, C.; Feng, M. Insulin-loaded ph-sensitive hyaluronic acid nanoparticles enhance transcellular delivery. AAPS PharmSciTech., 2012, 13 (3), 836-845.
113. Ma, E.-L.; Ma, H.; Liu, Z.; Zheng, C.-x.; Duan, M.-x. In vitro and in vivo evaluation of a novel oral insulin formulation. Acta. Pharmacol. Sin., 2006, 27 (10), 1382-1388.
114. Brogden, R. N.; Heel, R. C. Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs, 1987, 34, 350-371.